Formulation and evaluation of oral controlled release tablets of betahistine hydrochloride
International Journal of Development Research
Formulation and evaluation of oral controlled release tablets of betahistine hydrochloride
Received 14th February, 2023; Received in revised form 21st March, 2023; Accepted 29th March, 2023; Published online 30th April, 2023
Copyright©2023, Srinivas Nandyala. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The present study involves in the formulation and evaluation of Controlled release tablets of Betahistine HCl (16mg). The objective ofthe present study was to formulate Betahistine HCl Controlled release tablets by direct compression method by using HPMC K4M, Ethyl cellulose and Eudragit S-100.MCC was used as diluting agent, Magnesium Stearate was usedas a lubricant and Talc was used as a glident. This Controlled release the drug up to 12 hours in predeterminedrate. The formulated powder blend was evaluated for bulk density, tapped density, compressibility index and angle of repose. Theformulated tablets were evaluated for physical characteristics of Controlled release tablets such as thickness, hardness, friability,weight variation and drug content. The results of the formulations found to be within the limits specified in official books. Thetablets were evaluated for In-vitro drug release studies by using USP type II dissolution test apparatus. The dissolution test wasperformed in 0.1 N HCL for 2 hr and phosphate buffer pH 6.8 for 12hrs. The in-vitro cumulative drug release profile of all formulations F1-F12 hours showed good drug release. Hence, Formulation F7 was the most promisingformulation as it gives satisfactory release (98.29 %) for 12 hours and F7 found to be the best formulation.